Reduced-intensity conditioning consisted of fludarabine+busulfan 3.2 mg/kg per day × 2 days.
Myelofibrosis, a rare myeloproliferative neoplasm, is a clonal stem-cell disorder that leads to ineffective erythropoiesis and dysplastic megakaryocytic hyperplasia with an annual incidence of 1 per 100 000 in the United States. 1, 2 It has a mean survival of 6.5 years from the time of diagnosis but significant heterogeneity is present, and the survival is much shorter for patients with intermediate and high-risk disease. 3 Despite the rapid increase in the number of novel therapeutics being tested for the treatment of myelofibrosis, allogeneic hematopoietic cell transplant (AHCT) remains the only curative therapy. Generally, younger individuals with higher-risk disease are considered eligible if they have adequate performance status and a donor is available. Historically, however, published reports on AHCT in myelofibrosis demonstrate inadequate outcomes, with~3-year progression-free survival of 45-80%, non-relapse mortality of 10-25% and overall survival at 5 years in the 45-70% range. [4] [5] [6] [7] Ruxolitinib, an inhibitor of the JAK-STAT pathway, has been FDA-approved since November 2011 for the treatment of intermediate and high-risk myelofibrosis. In 2012, results of the COMFORT-I trial were announced, which showed that ruxolitinib, as compared with placebo, provided significant clinical benefits in patients with myelofibrosis by reducing spleen size, improving myelofibrosis-related symptoms and prolonging overall survival. 8, 9 Enlarged spleen size has been shown to correlate with high transplant-related mortality in myelofibrosis and reduction of splenomegaly can theoretically hasten hematologic recovery. 7 Since approval, the drug has been used by many institutions off-label prior to AHCT, based on the theory that smaller spleen size might improve engraftment and decrease transplant-related mortality. 10 On the basis of the literature, this approach produces mixed results. Two studies from Germany found encouraging early outcomes with the use of ruxolitinib before AHCT in patients with myelofibrosis though the sample size was small (14 and 22 patients) and follow-up was relatively short (9 and 12 months after AHCT, respectively). 11, 12 However, in December 2013, French researchers announced preliminary results of a prospective study of 23 patients. They reported several severe adverse events following ruxolitinib discontinuation, including tumor lysis syndrome and cardiogenic shock, resulting in two fatalities. 13 We obtained Institutional Review Board (IRB) approval for a retrospective analysis of consecutive patients who underwent AHCT for myelofibrosis at Medical College of Wisconsin between January 2012 and March 2014. The inclusion criteria were primary or secondary myelofibrosis (post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis), AHCT with matched related or unrelated donor for myelofibrosis and treatment with ruxolitinib prior to transplantation. Patient characteristics, drug-related adverse events including cardiac toxicity and outcomes including response, relapse, GvHD and overall survival were analyzed and herein reported.
Our cohort included 10 patients. Median age was 56 years (range 47-60 years) at the time of transplant. Four patients had de novo disease, and the remaining six had myelofibrosis that had evolved from a prior myeloproliferative neoplasm. All patients had splenomegaly; one of the 10 patients underwent splenectomy as part of the prior treatment. The majority (6 of 10) had intermediate II-risk disease by the Dynamic International Prognostic Scoring System (DIPSS). JAK2(V617F) mutation was present in seven patients, and two patients had received hydroxyurea as part of previous treatment. The baseline characteristics of patients are Abbreviations: AHCT = allogeneic hematopoietic cell transplant; CMV = cytomegalovirus; DIPSS = Dynamic International Prognostic Scoring System; ET = essential thrombocythemia; MF = myelofibrosis; PV = polycythemia vera; RSV = respiratory syncytial virus. a Myeloablative conditioning consisted of fludarabine+busulfan 3.2 mg/kg per day for 4 days. summarized in Table 1 . All 10 patients received ruxolitinib as pretreatment prior to transplant, and a standard taper schedule was employed starting 6 days prior to conditioning (Table 2) . Two patients had ruxolitinib discontinued prior to the tapering protocol-one patient stopped taking the drug after 3.5 months of exposure due to severe headache and the other patient was taken off ruxolitinib after 8 months of use due to progression of disease. The median duration of ruxolitinib administration was 180 days (range 56-270 days). A variety of dose levels were administered. Of the nine patients with splenomegaly, five had at least a modest reduction in spleen size (defined as reduction in spleen size of 10% or more) attributed to the medication, as measured on consecutive computerized tomography scans or ultrasonography. One patient experienced rebound splenomegaly after discontinuation of ruxolitinib. No patient experienced clinical symptoms of tumor lysis syndrome or cardiac toxicity upon ruxolitinib withdrawal.
Six of the 10 patients received myeloablative conditioning, and four were treated with reduced-intensity conditioning. Median time to engraftment was 17 days (range 13-22 days). Of the four patients who did not have any significant response to splenomegaly on ruxolitinib, two underwent myeloablative conditioning (spleen sizes 16 and 20 cm) and two received reduced-intensity conditioning (spleen sizes 28 and 26 cm). There was no significant difference in the time to neutrophil engraftment (14.5 and 18.5 days) or platelet engraftment (14 and 10.5 days) between the two groups. GvHD prophylaxis was provided in all patients with methotrexate and tacrolimus. Acute GvHD occurred in two patients but was ⩽ grade II in both. Chronic GvHD occurred in four patients; two were graded as mild and two were graded as moderate. After a median follow-up of 14.5 months (range 5-23 months), all 10 patients are alive. No patients require transfusions; one patient remains on intermittent granulocyte-colony stimulating factor for neutropenia. By International Working Group for Myelofibrosis Research and Treatment criteria (IWG-MRT), four patients achieved CR, two achieved PR, one had clinical improvement and three had stable disease. No patient has experienced transplant-related mortality or graft failure.
Although this study is too small to draw definitive conclusions, these results support the safety of ruxolitinib therapy prior to AHCT, provided a taper is used. We use a relatively rapid tapering protocol at our institution with the intention of suppressing rebound disease before a therapeutic intervention can be performed. We also hypothesize that the administration of ruxolitinib before AHCT in patients with myelofibrosis has beneficial effects on spleen size and potentially on engraftment. We did not observe any serious adverse events with ruxolitinib discontinuation pre-AHCT and no special safety concerns related to transplant in ruxolitinib-exposed patients who stopped drug 48 h prior to transplant. The differences between the toxicities reported by French investigators and our own experience may be related to differences in the tapering schedule. We and others participated in a larger, multi-institution retrospective study of similar patients, which was recently published.
14 Currently, the largest prospective international clinical trial to address this issue is underway, conducted by the Myeloproliferative Disorders Research Consortium (NCT01790295). 
